Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi And Selecta To Partner On Immunotherapies For Life-Threatening Allergies

This article was originally published in The Pink Sheet Daily

Executive Summary

Vaccine and immunotherapy-focused Selecta, up to now focused on grants for funding, signs its first big pharma partner around targeted, antigen-specific programs for undisclosed allergies.

You may also be interested in...

Deal Watch: U.S. Pharmas Look To Europe For Partners

Pfizer gained an option to acquire Dutch biopharma AM-Pharma, while Lilly hooked up with Germany’s BioNTech in a cancer immunotherapy pact. Juno acquired German biotech Stage Cell Therapeutics.

Merck’s Allergy Immunotherapy Suffers Review Delay Under Gov’t Shutdown

Without user fee coverage, advisory committees for Merck and Stallergenes’ new era grass allergy products must be pushed back from their scheduled November dates.

In Short Order, Merck And Stallergenes File BLAs For New Allergy Immunotherapies

Both Merck and French biotech Stallergenes have filed BLAs with FDA for approval of their respective grass allergy immunotherapies.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts